SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending due to its exceptionally active community passionately championing the "OG meme" narrative of Rage Comics, positioning it as the foundational "meme reset" for an upcoming market cycle. This dedicated base is consistently building out an ecosystem with tools like RageMaker and RageGames, expressing strong conviction for significant long-term growth and leadership in the meme coin space.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is generating significant buzz driven by the strong anticipation of the "Clarity Act" providing regulatory certainty and the growing scarcity indicated by multi-year low exchange supply. The community is expressing widespread bullish sentiment, believing XRP is poised for a major upward movement as it solidifies its role in global financial infrastructure, despite some historical volatility.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is garnering significant attention amid a rallying Bitcoin, fueling bullish sentiment that the company is an undervalued, leveraged play on the cryptocurrency. Community discussion is vibrant, with many anticipating MSTR's upside potential in line with Bitcoin's momentum, while others remain cautious due to ongoing share dilution and concerns over a potential index reclassification.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as market participants actively debate the broader implications of the US military operation in Venezuela and its potential impact on global stability and oil prices. Community sentiment is divided, with some anticipating a bullish market reaction due to access to vast oil reserves, while others express concerns about escalating geopolitical risks and potential retaliatory actions from other global powers. Amidst this, discussions also continue around the underlying strength of key semiconductor and AI-related stocks that heavily influence the tech-centric ETF.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is a major trending topic following its completed acquisition of Ask Sage and a substantial debt reduction initiative. The community is actively debating the strategic implications of potential share dilution against a much stronger balance sheet, while anticipating significant new contracts within the defense and secure AI sectors. Investors are keenly watching BBAI's positioning to become a leading player, drawing frequent comparisons to Palantir.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending following its acquisition of AI startup Manus, signaling a strategic pivot to enhance AI agent capabilities across its platforms. Many in the community view this as a potentially transformative step for future growth, drawing comparisons to past successful acquisitions and highlighting its role in the competitive AI landscape. However, a notable segment remains highly skeptical, labeling the increased AI spending as wasteful and predicting further share declines.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending with significant premarket gains as recent geopolitical developments in Venezuela, a nation with massive oil reserves, position the company uniquely. The community is actively discussing Chevron's strategic advantage as the sole major U.S. oil operator there, driving bullish sentiment amid global supply considerations.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a significant surge, driven by geopolitical developments in Venezuela which are reinforcing its narrative as 'digital gold' and a hedge against instability. Community sentiment is overwhelmingly bullish, with many celebrating short liquidations and anticipating further upward momentum amidst growing institutional interest and discussions around broader crypto integration into traditional finance.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record December and Q4 vehicle deliveries, bringing it close to one million cumulative units. Despite this strong operational performance and approaching profitability, the community is actively debating perceived stock manipulation, arguing that institutional short-selling is keeping shares significantly undervalued amidst its technological advancements like battery swapping.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is seeing renewed attention amid an optimistic outlook for AI infrastructure, driven by recent analyst upgrades and speculation around easing debt agreements and government contract activations. The community is actively debating its long-term potential, citing NVIDIA's backing and significant revenue backlog against concerns over its debt profile and past insider selling, as the broader sector anticipates key developments from upcoming tech events.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$HGENQ @VeryJerry hey Jerry. So being so close to this for a long time and therefore running the risk of losing objectively I asked a close friend of mine who’s a hardcore academic to have a look at the pre-print of LIVE-AIR for me…….his comments below.

b.roke

Thomas Smith

Gee Caps

Khalil

donkey punched by HGEN

seonghyun ryu

StockTwits for iOS

Humanigen Inc

 hey Jerry. So being so close to this for a long time and therefore running the risk of losing objectively I asked a close friend of mine who’s a hardcore academic to have a look at the pre-print of LIVE-AIR for me…….his comments below.

@VeryJerry I’ve finished reviewing that paper. My initial thoughts are: there are some pretty hardcore exclusions 1) pregnant/must agree to use contraception for a period of time after treatment. 2) can’t have IL-6 blockers which are established standard of care. The trial was done at 29 sites but only recruited 520 patients. This is always a worry for me as it implies there was some pretty strong screening processes going on at those sites. Were only the best possible candidate patients taken forward into the trial? There are some weird parts of the statistical analysis. The modified ITT analysis excluded a large number of patients who went onto IMV (the primary end point) because the hospital ran out of high flow O2. I’m not sure what to make of that. They do give the unmodified ITT which agrees largely with the mITT though. The KM curves are *only* shown for the mITT analysis, which I think is dodgy. I would have liked to have seen an as per protocol analysis for comparison.

 I’ve finished reviewing that paper. My initial thoughts are: there are some pretty hardcore exclusions 1) pregnant/must agree to use contraception for a period of time after treatment. 2) can’t have IL-6 blockers which are established standard of care. The trial was done at 29 sites but only recruited 520 patients. This is always a worry for me as it implies there was some pretty strong screening processes going on at those sites. Were only the best possible candidate patients taken forward into the trial? There are some weird parts of the statistical analysis. The modified ITT analysis excluded a large number of patients who went onto IMV (the primary end point) because the hospital ran out of high flow O2. I’m not sure what to make of that. They do give the unmodified ITT which agrees largely with the mITT though. The KM curves are *only* shown for the mITT analysis, which I think is dodgy. I would have liked to have seen an as per protocol analysis for comparison.

@VeryJerry A lot of the secondary end points do not appear to be pre-specified, and so I don’t think we should interpret them too strongly. Lastly, in the discussion, they make a big argument against Tocilizumab, by casting doubt over its efficacy. This is disingenuous as a large meta-analysis now shows that tocilizumab is clearly efficacious, though it is difficult to say if it is more or less efficacious than Lenzilumab based on this study.

 A lot of the secondary end points do not appear to be pre-specified, and so I don’t think we should interpret them too strongly. Lastly, in the discussion, they make a big argument against Tocilizumab, by casting doubt over its efficacy. This is disingenuous as a large meta-analysis now shows that tocilizumab is clearly efficacious, though it is difficult to say if it is more or less efficacious than Lenzilumab based on this study.

@VeryJerry In short. The paper reads like it was written by a drug company, and I think that was a mistake. I think the big journals will probably see through that, and either ask for a re-write so it is more balanced, or they will just reject it. It depends on how greedy the big journals are feeling, as this will obviously get good press

Oh, and the pre-registration for the trial lists 18 pre-specified secondary end points. Most of which aren’t reported. Instead they report some different ones.

 In short. The paper reads like it was written by a drug company, and I think that was a mistake. I think the big journals will probably see through that, and either ask for a re-write so it is more balanced, or they will just reject it. It depends on how greedy the big journals are feeling, as this will obviously get good press

Oh, and the pre-registration for the trial lists 18 pre-specified secondary end points. Most of which aren’t reported. Instead they report some different ones.

@VeryJerry So I think there is definitely potential here. The drug needs further evaluation from an external sponsor. But the IL-6 exclusion is going to make that logistically very difficult.

I suppose a good way to run a trial would be to put Tocilizumab vs. Lenzilumab head to head

 So I think there is definitely potential here. The drug needs further evaluation from an external sponsor. But the IL-6 exclusion is going to make that logistically very difficult.

I suppose a good way to run a trial would be to put Tocilizumab vs. Lenzilumab head to head

@VeryJerry my thoughts:
A lot of what he’s said is fair to pick up like the mITT question which I think has been adequately answered although is a fair point to pick up on when reading the paper for the first time with no background.
Also as I said he is a pure academic and this is is part academia and part commercial and I personally think Mayo running stamping things will take care of that concern.
Additionally I’m pretty sure there will never be a Lenz, Toc trial on grounds of cost, ethics, time and general pragmatism 
The only thing I wasn’t sure about was absolute comparison to Toc efficacy……have you got any evidence to hand quickly to answer that query??
Thanks

 my thoughts:
A lot of what he’s said is fair to pick up like the mITT question which I think has been adequately answered although is a fair point to pick up on when reading the paper for the first time with no background.
Also as I said he is a pure academic and this is is part academia and part commercial and I personally think Mayo running stamping things will take care of that concern.
Additionally I’m pretty sure there will never be a Lenz, Toc trial on grounds of cost, ethics, time and general pragmatism 
The only thing I wasn’t sure about was absolute comparison to Toc efficacy……have you got any evidence to hand quickly to answer that query??
Thanks

@Sheriff_Nottingham thanks for sharing , always appreciate an objective viewpoint and always up for constructive debate :) 

I think you touched on the first two points - the paper is a Mayo Clinic paper with the head of the covid task force attached so no journal will have an issue publishing their POV. Lenz is already being studied and sponsored by various organizations across different indications (see pipeline) but also in covid by the NIH. The guidelines released yesterday really lend a lot of credibility to the trial results as well. I’ll post screenshot below.

As far as the main point I think here is , is Lenzilumab better than Tocilizumab? My answer is that based on the data it should be used at a completely different stage of disease course so it’s hard to compare the two. As far as head to head here is the chart Humanigen published when compared to the Recovery Trial (main trial used for EUA)

Dale

Marvin Wehrli

Ryan

Roger jorah

Jerry

here2edify

 thanks for sharing , always appreciate an objective viewpoint and always up for constructive debate :) 

I think you touched on the first two points - the paper is a Mayo Clinic paper with the head of the covid task force attached so no journal will have an issue publishing their POV. Lenz is already being studied and sponsored by various organizations across different indications (see pipeline) but also in covid by the NIH. The guidelines released yesterday really lend a lot of credibility to the trial results as well. I’ll post screenshot below.

As far as the main point I think here is , is Lenzilumab better than Tocilizumab? My answer is that based on the data it should be used at a completely different stage of disease course so it’s hard to compare the two. As far as head to head here is the chart Humanigen published when compared to the Recovery Trial (main trial used for EUA)

@VeryJerry thanks Jerry. My understanding Was Toc was to be used later in the progression. Is that part of the formal EUA licensing or is it granted for all severe/critical (ie ordinal 3 onwards)?

 thanks Jerry. My understanding Was Toc was to be used later in the progression. Is that part of the formal EUA licensing or is it granted for all severe/critical (ie ordinal 3 onwards)?

@Sheriff_Nottingham it’s currently granted for all severe/critical - as long as it’s used with steroids. 

Based on the exploratory analysis LIVE-AIR it’s clear that Lenz should be used early in hospitalization. 

It makes a lot of sense as increased Levels of Gm-CSF upregulate IL-6 along with a host of other cytokines 

Earlier treatment will prevent progression to severe course disease and that’s what the goal is of any hospital right?

 it’s currently granted for all severe/critical - as long as it’s used with steroids. 

Based on the exploratory analysis LIVE-AIR it’s clear that Lenz should be used early in hospitalization. 

It makes a lot of sense as increased Levels of Gm-CSF upregulate IL-6 along with a host of other cytokines 

Earlier treatment will prevent progression to severe course disease and that’s what the goal is of any hospital right?

@VeryJerry I don’t know your sense of humour but this tickled me. I sent the guy that provided that review a précis of your retorts which is what the allying fear comment relates to……..this was his reply. If you want someone to find any flaw in any paper this is your guy because he’s so focused on the science and methodology! His responses have only made me more bullish!

 I don’t know your sense of humour but this tickled me. I sent the guy that provided that review a précis of your retorts which is what the allying fear comment relates to……..this was his reply. If you want someone to find any flaw in any paper this is your guy because he’s so focused on the science and methodology! His responses have only made me more bullish!

@Sheriff_Nottingham I never take offense to good debate , in fact I would be worried if people had only positive things to say. 

Send him the nick mark Twitter thread and see what he says.. 

I’d also suggest that he take a read of the thwaites paper to get started - 

https://immunology.sciencemag.org/content/6/57/eabg9873

Remember this trial was started at the outset of the pandemic - it was designed before we learned many things about covid progression that we know today. I’d say they did a damn good job either way butThere’s a reason why many things in live-air were not pre specified , because we learned them along the way with papers like thwaites.

Critical respiratory failure in COVID-19 is an inflammatory disease-several proinflammatory factors correlate with disease severity in COVID-19, and anti-inflammatory treatments such as corticosteroids and anti-IL-6 monoclonal antibodies can reduce mortality. There is a need to identify additional "targetable" proinflammatory factors that correlate with disease severity. Here, Thwaites et al .

Science Immunology

Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19

 I never take offense to good debate , in fact I would be worried if people had only positive things to say. 

Send him the nick mark Twitter thread and see what he says.. 

I’d also suggest that he take a read of the thwaites paper to get started - 





Remember this trial was started at the outset of the pandemic - it was designed before we learned many things about covid progression that we know today. I’d say they did a damn good job either way butThere’s a reason why many things in live-air were not pre specified , because we learned them along the way with papers like thwaites.

@Sheriff_Nottingham @VeryJerry I want to thank you for the discussion here. Though I have nothing to add I learned a lot from reading both your perspectives.

ThetaPlay

DrixGod

StockTwits For Android 

 I want to thank you for the discussion here. Though I have nothing to add I learned a lot from reading both your perspectives.